Trial Profile
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Proof of Concept Comparison Study of the Safety and Efficacy of DUR-928 Topical Solution With Occlusion in Subjects With Mild to Moderate Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Larsucosterol (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- 28 May 2020 Status changed from active, no longer recruiting to completed.
- 03 Mar 2020 According to a DURECT Corporation media release, twenty-two patients completed the study.
- 08 Jan 2020 Planned End Date changed from 1 Oct 2019 to 1 Mar 2020.